Intellia Therapeutics (NTLA) Current Deferred Revenue (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Current Deferred Revenue data on file, last reported at $630000.0 in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $630000.0, down 98.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $630000.0 (down 98.14% YoY), and the FY2025 annual result was $7.3 million, down 81.27% from the prior year.
• Current Deferred Revenue eased to $630000.0 in Q1 2026 per NTLA's latest filing, from $7.3 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $113.2 million in Q1 2022 and troughed at $630000.0 in Q1 2026.
• A 5-year average of $46.3 million and a median of $44.8 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue jumped 71.73% in 2024, then sank 98.14% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $63.8 million in 2022, then retreated by 4.36% to $61.0 million in 2023, then tumbled by 36.19% to $38.9 million in 2024, then slumped by 81.27% to $7.3 million in 2025, then plunged by 91.36% to $630000.0 in 2026.
• Business Quant data shows NTLA's Current Deferred Revenue at $630000.0 in Q1 2026, $7.3 million in Q4 2025, and $12.2 million in Q3 2025.